Histometrics

BDC · CEF Analytics

Public Reference

Industry Primers

Bottom-up NAICS industry primers written for both public-market and private investors. Leaf industries are researched from the ground up; every group, subsector, and sector above them reads as a contrast across the industries beneath it.

2122 industries · 24 sectors · NAICS 2022

Researched with AI assistance from official U.S. statistics and independent sources, with citations on every page. Figures are not individually verified against pinned evidence — primers marked Evidence-verified are. Industry research, not investment advice. Methodology.

National industryNAICS 334516

Analytical Laboratory Instrument Manufacturing (U.S.) — NAICS 334516

An investor's primer. Figures are reported facts with citations; statements about the future are labeled as outlook or judgment.

1. Overview

Analytical laboratory instruments are the machines that tell a lab what a sample is made of and how much. When a drugmaker checks that a pill contains the right dose and no toxic impurity, when a water utility screens for "forever chemicals," when a chip foundry verifies material purity, or when a hospital lab confirms a drug level in blood — an instrument from this industry did the measuring. The core product families are chromatography (separating a mixture into its parts), mass spectrometry (identifying molecules by weight), spectroscopy (using light to fingerprint composition), and automated chemical analyzers.[1][5]

Why an investor should care: this is a picks-and-shovels business sitting underneath pharmaceuticals, biotech, environmental testing, food safety, semiconductors, and clinical diagnostics. Owners make money less from selling the machine than from the decade-long stream of consumables, service, and software that flows once a machine is installed — a durable, high-margin "razor-and-blades" model with strong regulatory lock-in.[15]

Ways in: the public route is a handful of large, diversified "life-science tools" companies whose analytical-instrument lines are one slice of a bigger portfolio (Section 4). The private route is a long tail of specialist and family-owned instrument makers, private-equity roll-ups, and venture-backed startups building next-generation instruments — most of whom eventually exit by being acquired by one of the public giants (Sections 4, 10).

2. What it is, and what it excludes

NAICS (North American Industry Classification System) code 334516 covers establishments that primarily make instruments for laboratory analysis of the chemical or physical composition or concentration of solid, liquid, gas, or composite samples.[1] Typical products: liquid and gas chromatographs (HPLC/GC — high-performance liquid chromatography and gas chromatography), mass spectrometers (MS), spectrophotometers (atomic absorption, infrared, Raman, fluorescence, UV-visible), nuclear magnetic resonance (NMR) systems, X-ray analysis, thermal analyzers, rheometers, calorimeters, elemental analyzers, and automatic chemical analyzers.[1]

What it excludes (adjacent codes an investor should not conflate):

  • 334510 – Electromedical and Electrotherapeutic Apparatus: instruments that monitor or analyze samples drawn continuously from a patient (i.e., bedside/clinical monitoring).[1]
  • 334513 – Instruments for Measuring, Displaying, and Controlling Industrial Process Variables: in-line sensors that measure or control a factory process rather than analyze a discrete lab sample.[1]
  • Reagents and test kits (the chemistry consumed by the machines) largely sit in in-vitro-diagnostic and chemical-manufacturing codes (e.g., NAICS 325413), not here — an important reason the federal revenue figure below understates the "analytical instruments" business as investors think of it.

Ownership mix: a few global, publicly traded multinationals dominate the technology and brand share, sitting atop a fragmented tail of hundreds of smaller domestic firms — many private, family-owned, or private-equity-held niche specialists.[3][5]

3. How big it is (U.S. federal statistics)

Ground-truth federal figures for the U.S. industry:

Metric Value Source
Industry receipts (revenue) $19.35 billion Economic Census 2022[3]
Establishments 652 County Business Patterns 2023[2]
Firms 629 Economic Census 2022[3]
Employment 50,576 County Business Patterns 2023[2]
Annual payroll $5.74 billion (≈ $113k/worker) County Business Patterns 2023[2]
4-firm concentration (CR4) 25.2% Economic Census 2022[3]
8-firm / 20-firm / 50-firm 40.2% / 60.7% / 78.7% Economic Census 2022[3]
HHI (Herfindahl-Hirschman Index) 273 Economic Census 2022[3]
SBA small-business size standard 1,000 employees SBA 2023[4]

Read the numbers carefully. The $19.35 billion counts the value of what is manufactured in U.S. establishments classified here. It is a genuine undercount of the industry an investor cares about, for three reasons: (a) much of the instrument revenue booked by the U.S. leaders is manufactured or sold outside the U.S.; (b) the lucrative recurring streams — consumables, service contracts, software — are often classified in other industry codes; and (c) a large share of instruments used in U.S. labs are imported. For scale, third-party research pegs the global analytical-instrumentation market near $55 billion in 2024, with North America about 47% of it.[5] Note also that the 652 establishments do not mean 652 independent competitors: a multi-site manufacturer can contribute multiple establishments, and a diversified company may have only some facilities classified in 334516.[2] The concentration story is also two-sided: the low CR4 (25%) and low HHI (273) say no single U.S. manufacturing establishment dominates domestic production — but at the global brand level the industry is a tight oligopoly of the companies in Section 4.[3][5]

4. The investable universe

There is no pure-play "analytical instruments" public stock — every large public name is a diversified life-science-tools company where analytical instruments are one line of business. Tickers and scale below are for the whole company or its relevant segment; treat them as exposure to the theme, not a pure bet.

Company Ticker Relevant scale (latest fiscal year) Notes
Thermo Fisher Scientific TMO Analytical Instruments segment $7.55B (FY2025); 23.0% segment margin Largest player; chromatography, MS, spectroscopy[6]
Danaher DHR Life Sciences segment $7.33B (FY2024) Owns SCIEX (MS), Leica, Beckman Coulter Life Sciences, Molecular Devices[8]
Agilent Technologies A $6.95B total (FY2025); 52.4% gross / 21.3% operating margin Chromatography/MS leader; 29% of revenue from services[7]
Mettler-Toledo MTD $3.9B total (FY2024); ~58% gross margin Precision balances, lab & industrial analytics[9]
Bruker BRKR $3.37B total (FY2024; +13.6% YoY) NMR, mass spec, materials/scientific instruments[10]
Waters WAT $3.17B standalone (FY2025); ~$803M operating income HPLC/MS; merged with BD's biosciences unit Feb 2026[11][13]
Revvity (ex-PerkinElmer) RVTY $2.76B total (FY2024) Reagents, imaging, diagnostics; applied business sold to PE[12][21]

Major private / non-U.S. owners: Shimadzu, Horiba, and JEOL (publicly listed in Japan); Sartorius, Carl Zeiss, and Spectris (Europe); Oxford Instruments (UK); and privately held specialists such as Metrohm, LECO, Anton Paar (foundation-owned; invests ~14.5% of turnover in R&D), and the former PerkinElmer applied-instruments platform now owned by New Mountain Capital (acquired 2023 for up to $2.45 billion).[8][20][21] Danaher's applied-instruments and water-quality lines were spun off in 2023 as Veralto (VLTO). A dense tail of the ~629 U.S. firms are private niche makers.[3]

5. How the money works

The economics are best understood as install the razor, sell the blades:

  • The instrument (the razor): a capital purchase — often $50k to $1M+ — that is lower-margin, lumpier, and cyclical because customers can defer it when budgets tighten. Winning the placement is what matters; it seeds years of downstream revenue.
  • The blades (recurring revenue): consumables (chromatography columns, vials, reagents, chips), multi-year service and maintenance contracts, and informatics/software. These carry much higher margins and recur predictably. Industry analysis estimates recurring revenue is roughly 80%+ of sales at the largest players (e.g., ~83% at Thermo Fisher, ~81% at Danaher).[15]
  • The moat is regulatory lock-in. Once a lab validates an instrument and method for a regulated workflow (see Section 7), switching to a rival means re-validating — costly and time-consuming. That switching cost entrenches the installed base and protects its consumable/service annuity. Gross margins in the high-50s%+ (e.g., Mettler-Toledo, Agilent) reflect this pricing power.[7][9][15]

Waters illustrates the revenue mix: in FY2025 it reported $1.35B of instrument systems, $632M of chemistry consumables, and $1.19B of service — showing that recurring/repeat streams roughly equal or exceed new-instrument sales.[11]

The production model: manufacturers typically design the proprietary measurement architecture and software, then perform critical machining, assembly, calibration, and quality control internally while outsourcing commodity components (computers, circuit boards, some modules). Field engineers install systems, train customers, and minimize downtime; applications specialists help customers develop methods and workflows.[11]

What to watch: instrument orders / book-to-bill / backlog are the leading indicators (they signal future consumable pull-through); the recurring-revenue mix signals downturn resilience; R&D intensity (typically ~8–12% of sales; specialist Anton Paar invests ~14.5%) sustains the performance edge; and geographic and currency mix matters because most leaders earn the majority of revenue outside the U.S.[6][7][15][20]

6. What drives demand

  • Pharma and biopharma R&D and quality control — the single biggest driver. Biologics, cell-and-gene therapy, mRNA, and the GLP-1 boom all require heavy analytical characterization at discovery, manufacturing, and QC.[5]
  • Academic and government research funding — grant dollars (in the U.S., largely NIH and NSF) buy new instruments and the reagents to run them. NIH's FY2025 appropriation totaled $48.5 billion, with $35.3 billion awarded through competing and noncompeting grants — a large base, but timing follows grants and appropriations.[16][22]
  • Environmental testing — PFAS ("forever chemicals") regulation, water and air monitoring; EPA Methods 533 and 537.1 together can measure 29 PFAS compounds in drinking water via LC-MS/MS, creating mandated instrument demand.[19][23]
  • Food and beverage safety, forensics, cannabis, and battery/energy materials — steady applied-market demand.
  • Semiconductors and advanced materials — purity and metrology needs tied to the chip build-out.[5]
  • Clinical diagnostics — mass spectrometry is migrating from the research bench into routine clinical labs, a structural growth lane.[5]
  • China and emerging markets — a major swing factor: Chinese biopharma R&D and licensing has surged (China-origin licensing deals rose from ~$5B in 2020 to over $50B in 2024), even as near-term Chinese instrument demand has been soft.[18]

7. Regulation

The instruments are mostly not regulated as products (they are not medical devices when used for research or QC), but how they are used is heavily regulated, and that regulation is the demand engine and the moat:

  • FDA Good Manufacturing Practice (GMP; 21 CFR 210/211) and Good Laboratory Practice (GLP; 21 CFR 58) govern regulated drug/lab work.
  • 21 CFR Part 11 governs electronic records and data integrity — instruments and their software must be compliant.[14]
  • USP <1058> Analytical Instrument Qualification (AIQ) (USP = United States Pharmacopeia) sets the framework for proving an instrument is fit for use; ICH Q2 governs method validation.[14]
  • EPA test methods (e.g., PFAS methods 533, 537.1, 1633) and ISO/IEC 17025 lab accreditation mandate specific instrumentation and validated procedures.[19][23]

Two regulatory edges to note: when instruments cross into clinical diagnostics, they become IVDs (in-vitro-diagnostics) subject to FDA premarket review, establishment registration, labeling, and quality-system requirements — adding cost and time but also a regulatory moat; this was a factor in the Waters–BD deal.[13][24] And high-end instruments can be subject to export controls and, increasingly, tariffs.[17]

8. Competitive dynamics and consolidation

The industry is a consolidated oligopoly of diversified multinationals with a fragmented specialist tail. Competitive barriers are steep: R&D scale, a validated installed base, global service/field-engineering networks, and deep regulatory relationships.[5][15]

Consolidation is relentless, led by serial acquirers — Danaher (built Life Sciences via Leica, SCIEX, Beckman Coulter, Pall, Abcam and its "Danaher Business System" playbook) and Thermo Fisher.[8] The landmark recent move: in July 2025 Waters agreed to combine with BD's Biosciences & Diagnostic Solutions business in a ~$17.5 billion Reverse Morris Trust deal (BD shareholders ~39.2%, Waters ~60.8%), creating a ~$6.5B-revenue leader in regulated, high-volume testing; the transaction closed February 9, 2026.[13] Private equity is also active: New Mountain Capital acquired the former PerkinElmer applied, food, and enterprise-services platform in 2023 for up to $2.45 billion.[21] Startups and PE-owned specialists mostly exit by being acquired into one of these platforms — corporate M&A is the industry's dominant liquidity path.[8][13]

9. Risks

  • Capital-equipment cyclicality. Instrument purchases are deferrable; when customer capex tightens, placements fall first. Agilent's revenue declined 5% in fiscal 2024 amid pharma and chemical/applied-materials capital-spending pressure before rebounding 7% in fiscal 2025.[6][7]
  • Research-funding cuts. In 2025 the U.S. administration moved to cap NIH indirect-cost reimbursement (toward 15%) and terminated billions in grants across hundreds of institutions — a direct headwind to academic instrument and consumable demand.[16]
  • China exposure. Soft Chinese demand, tariffs on Chinese imports (raised sharply in 2025), "buy-local" procurement, and potential export controls all bite. Thermo Fisher attributed part of its FY2025 margin compression to tariffs and related FX.[6][17]
  • Biotech funding cycles. Venture/IPO "winters" cut emerging-biopharma instrument budgets.
  • Currency (FX). Most leaders earn the majority of revenue abroad; a strong dollar compresses reported results.[6]
  • Post-COVID destocking. Normalization of consumable inventories has pressured recurring revenue growth.[12]
  • Supply-chain concentration. Many systems use specialized, qualified components from limited or single sources; supplier shutdowns, sanctions, or the time required to qualify replacements can delay shipments.[11]
  • Integration and execution risk on large M&A (e.g., Waters–BD).[13]

10. How to invest, and the outlook

Public routes. Exposure comes through the diversified names in Section 4 (TMO, DHR, A, MTD, BRKR, WAT, RVTY) and non-U.S. listings (Shimadzu, Horiba, JEOL in Tokyo; Sartorius in Frankfurt/Paris; Oxford Instruments and Spectris in London). Remember these are tools companies — analytical instruments are one slice, so investors get the theme plus reagents, bioprocessing, and diagnostics. Waters, at ~$3.2B in standalone revenue, is the closest large listed pure play, though even it combines instruments, consumables, service, and software globally — and its FY2025 results predate inclusion of BD Biosciences, complicating trend analysis.[11] There is no pure-play analytical-instruments ETF; broad life-science-tools and health-care funds are the closest packaged exposure. Reserve valuation work (multiples, dividend yields) for the specific ticker — as a group these trade as quality compounders on the strength of their recurring revenue.

Private routes. Direct ownership sits in PE-held specialists and roll-ups, and in venture-backed startups building next-generation instruments (single-cell and spatial biology, portable/handheld spectroscopy, AI-enabled spectral interpretation, automated sample prep). Attractive targets generally possess a defensible measurement niche, a growing installed base, high service attachment, proprietary consumable pull-through, and limited customer concentration. Founder-, family-, and foundation-owned competitors such as LECO and Anton Paar show that meaningful private assets remain outside the public consolidators. For most private instrument makers, the realistic exit is acquisition by a strategic buyer rather than an IPO.[8][13]

Outlook (forward-looking judgment). Near term is muted: soft China, academic-funding uncertainty, and lingering consumable destocking are weighing on instrument placements through 2025–26.[16][17] But the structural tailwinds are intact — biologics and GLP-1 drugs, cell-and-gene therapy, PFAS and environmental testing, clinical mass spectrometry, and reshoring of pharmaceutical manufacturing all expand the installed base and its recurring annuity.[5][19] The key swing factor to watch is the recovery in instrument orders: because every placement seeds years of high-margin consumable and service revenue, a rebound in book-to-bill would be the clearest signal that the next up-cycle has begun.

Sources

  1. U.S. Census Bureau / NAICS Association. "NAICS Code 334516 — Analytical Laboratory Instrument Manufacturing (2022 definition and cross-references)." 2022. https://www.naics.com/naics-code-description/?code=334516
  2. U.S. Census Bureau. "County Business Patterns, NAICS 334516." 2023. https://www.census.gov/programs-surveys/cbp.html
  3. U.S. Census Bureau. "Economic Census 2022 — Concentration and receipts, NAICS 334516." 2022. https://www.census.gov/programs-surveys/economic-census.html
  4. U.S. Small Business Administration. "Table of Small Business Size Standards (NAICS 334516 = 1,000 employees)." 2023. https://www.sba.gov/document/support-table-size-standards
  5. Grand View Research. "Analytical Instrumentation Market Size, Share & Trends (~$55B in 2024; North America ~47%)." 2025. https://www.grandviewresearch.com/industry-analysis/analytical-instrumentation-market-report
  6. Thermo Fisher Scientific. "2025 Annual Report / Form 10-K (Analytical Instruments segment $7,554M; 23.0% segment margin)." 2026. https://www.sec.gov/Archives/edgar/data/97745/000009774526000018/tmo-20251231.htm
  7. Agilent Technologies. "Fiscal Year 2025 Form 10-K ($6.948B; 52.4% gross margin; 21.3% operating margin)." 2025. https://www.sec.gov/Archives/edgar/data/1090872/000109087225000087/a-20251031.htm
  8. Danaher Corporation. "2024 Annual Report / Form 10-K (Life Sciences segment $7,329M)." 2025. https://www.sec.gov/Archives/edgar/data/313616/000031361625000085/danaher2024annualreport.htm
  9. Mettler-Toledo International. "Fourth Quarter 2024 Results (net sales $3.9B)." 2025. https://investor.mt.com/news/news-details/2025/Mettler-Toledo-International-Inc.-Reports-Fourth-Quarter-2024-Results/
  10. Bruker Corporation. "Fourth Quarter and Full Year 2024 Financial Results ($3.37B)." 2025. https://ir.bruker.com/press-releases/press-release-details/2025/Bruker-Reports-Fourth-Quarter-and-Full-Year-2024-Financial-Results/default.aspx
  11. Waters Corporation. "2025 Form 10-K ($3.165B; $1,346M instruments, $631.5M consumables, $1,188M service; $803M operating income)." 2026. https://www.sec.gov/Archives/edgar/data/1000697/000119312526062604/d778470d10k.htm
  12. Revvity, Inc. "Financial Results for the Fourth Quarter and Full Year of 2024 ($2.76B)." 2025. https://ir.revvity.com/news/investor-news/news-details/2025/Revvity-Announces-Financial-Results-for-the-Fourth-Quarter-and-Full-Year-of-2024/
  13. Waters Corporation / MedTech Dive. "Waters and BD's Biosciences & Diagnostic Solutions business to combine (~$17.5B; closed Feb 9, 2026)." 2025. https://www.medtechdive.com/news/Waters-BD-merger-biosciences-diagnostics-spinoff/752962/
  14. Malvern Panalytical / U.S. FDA. "21 CFR Part 11 and USP <1058> Analytical Instrument Qualification." 2024. https://www.malvernpanalytical.com/en/products/industry-standards/21-cfr-part-11
  15. ZERO (note.com). "Why Analytical Instrument Manufacturers Are Strong: recurring revenue / razor-and-blades (Thermo ~83%, Danaher ~81%)." 2024. https://note.com/all_zero/n/nc9f7d8527852?hl=en
  16. Science / AAAS and STAT. "NIH funding cuts, indirect-cost cap and grant terminations, 2025." 2025. https://www.science.org/content/article/final-funding-bill-nih-pushes-back-against-trump-cuts
  17. Pivotal Scientific. "Implications of U.S. Trade Tariffs & Funding Cuts for the Life Science Market." 2025. https://pivotalscientific.com/scientific-library/us-tariffs-funding-cuts/
  18. Nature. "China's increasing flow of innovative assets into big pharma R&D pipelines (licensing ~$5B in 2020 to >$50B in 2024)." 2025. https://www.nature.com/articles/d43747-025-00065-7
  19. GlobeNewswire / Research and Markets. "U.S. PFAS Analytical Instrumentation Market Report 2025." 2025. https://www.globenewswire.com/news-release/2025/04/09/3058222/28124/en/U-S-PFAS-Analytical-Instrumentation-Market-Report-2025.html
  20. Anton Paar. "Company Profile (foundation-owned; ~14.5% of turnover in R&D)." 2025. https://www.anton-paar.com/corp-en/about-us/company/
  21. Revvity / PerkinElmer. "SEC Filing: Sale of Applied, Food, and Enterprise Services to New Mountain Capital (up to $2.45B)." 2023. https://www.sec.gov/Archives/edgar/data/31791/000003179123000008/pki-20230402.htm
  22. NIH Office of Extramural Research. "Fiscal Year 2025 By the Numbers: Extramural Grant Investments ($48.5B appropriation; $35.3B awarded through grants)." 2026. https://grants.nih.gov/news-events/nih-extramural-nexus-news/2026/03/fiscal-year-2025-by-the-numbers-extramural-grant-investments-in-research
  23. U.S. EPA. "EPA PFAS Drinking Water Laboratory Methods (Methods 533 and 537.1 — 29 PFAS compounds)." 2025. https://www.epa.gov/pfas/epa-pfas-drinking-water-laboratory-methods
  24. U.S. FDA. "Overview of IVD Regulation." 2025. https://www.fda.gov/medical-devices/ivd-regulatory-assistance/overview-ivd-regulation